When presenting human cell and tissue products (HCTPs) to patients, providers should avoid unregulated terms like “stem cells” and instead focus on tissue-specific supplementation for cartilage-based defects, explaining that these products supply collagenic growth factors (like type I, II, and III collagen) that may help the body heal itself at a cellular level—especially when inflammation is controlled. By using FDA-aligned language, discussing patient-specific regenerative capacity, and matching graft complexity to injury severity and age, clinicians can ethically and effectively guide patients through their options.